Claims for Patent: 7,744,886

✉ Email this page to a colleague

Summary for Patent: 7,744,886

Title:	Methods for interfering with rank signaling
Abstract:	Disclosed herein are methods for interfering with RANK signaling by administering blocking antibodies that bind a RANKL polypeptide and inhibit the binding of the RANKL polypeptide to a RANK polypeptide.
Inventor(s):	Anderson; Dirk M (Port Townsend, WA)
Assignee:	Immunex Corporation (Thousand Oaks, CA)
Application Number:	12/214,914
Patent Claims:	1. A method of interfering with RANK signaling comprising administering an effective amount of a blocking antibody, wherein the blocking antibody binds to a human RANKL polypeptide as shown in SEQ ID NO:13 and inhibits the binding of the human RANKL polypeptide to a human RANK polypeptide as shown in SEQ ID NO:6, thereby inhibiting RANK signaling. 2. A method of claim 1, wherein the blocking antibody is a monoclonal antibody. 3. A method of interfering with RANK signaling comprising administering an effective amount of a blocking antibody, wherein the blocking antibody binds to a fragment of a human RANKL polypeptide as shown in SEQ ID NO:13 and inhibits the binding of the human RANKL polypeptide to a human RANK polypeptide as shown in SEQ ID NO:6, thereby inhibiting RANK signaling, wherein the fragment is selected from the group consisting of a) an extracellular domain comprising amino acids 69-317 of SEQ ID NO:13, and b) a receptor binding domain comprising amino acids 162-317 of SEQ ID NO:13. 4. A method of claim 3, wherein the blocking antibody is a monoclonal antibody.

Details for Patent 7,744,886

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	PROLIA	denosumab	Injection	125320	June 01, 2010	⤷ Subscribe	2016-12-23
Amgen Inc.	XGEVA	denosumab	Injection	125320	November 18, 2010	⤷ Subscribe	2016-12-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 7,744,886

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	9958674	⤷ Subscribe
World Intellectual Property Organization (WIPO)	9828426	⤷ Subscribe
World Intellectual Property Organization (WIPO)	9828424	⤷ Subscribe
United States of America	8715683	⤷ Subscribe
United States of America	8569456	⤷ Subscribe
United States of America	8377690	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.